Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 2/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | BLM | P54132 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | MTOR | P42345 | 2/20 | 0.56 |
| ▸ | NSD2 | O96028 | 2/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.56 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Banoxantrone SCHEMBL29378863 | 1.00 | NQO1 (0.72) | NQO1CYP19A1MEN1KMT2ABLM | |
| Banoxantrone SCHEMBL30324147 | 0.98 | NQO1 (0.70) | NQO1CYP19A1MEN1KMT2ABLM | |
| SCHEMBL13331702 | 0.94 | NQO1 (0.66) | NQO1CYP19A1MEN1KMT2ABLM | |
| SCHEMBL14369957 | 0.92 | NQO1 (0.64) | NQO1CYP19A1MEN1KMT2ABLM | |
| SCHEMBL14369959 | 0.91 | NQO1 (0.79) | NQO1CYP19A1MEN1KMT2ABLM | |
| Banoxantrone SCHEMBL17207287 | 0.90 | NQO1 (0.61) | NQO1CYP19A1MEN1KMT2ABLM | |
| SCHEMBL17207286 | 0.90 | NQO1 (0.61) | NQO1CYP19A1MEN1KMT2ABLM | |
| SCHEMBL9364140 | 0.90 | MEN1 (0.76) | NQO1CYP19A1MEN1KMT2ABLM | |
| SCHEMBL14876631 | 0.88 | CYP19A1 (0.62) | NQO1CYP19A1MEN1KMT2ABLM | |
| SCHEMBL17207292 | 0.87 | NQO1 (0.58) | NQO1CYP19A1MEN1KMT2ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| US-12584131-B2 | Methods of gene therapy | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-03-24 | — | — | US | claimed |
| US-12564728-B2 | Treatment of central nervous system disorders | KNOW BIO, LLC (US) | 2026-03-03 | — | — | US | claimed |
| EP-4676551-A1 | RADIATION SPACER HYDROGELS, METHODS OF FORMING, AND METHODS OF USE | Clearstream Technologies Limited (IE) | 2026-01-14 | — | — | EP | claimed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | claimed |
| EP-4615521-A1 | KETO-AMIDE-BASED FIBROBLAST ACTIVATION PROTEIN-TARGETED LIGAND LINKED TO AN IMAGING OR THERAPEUTIC AGENT, COMPOSITIONS AND METHODS OF USE | Purdue Research Foundation (US) | 2025-09-17 | — | — | EP | claimed |
| EP-2857018-B1 | Treatment or prophylaxis of proliferative conditions | UNIV COURT OF THE UNIV OF DUNDEE (GB) | 2025-09-03 | — | — | EP | claimed |
| EP-4587062-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | Cellis AG (CH) | 2025-07-23 | — | — | EP | claimed |
| CN-119907692-A | Isolated targeted delivery system for the treatment of gliomas | 塞尔丽思股份公司 | 2025-04-29 | — | — | CN | claimed |
| EP-4010072-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | KNOW Bio, LLC (US) | 2022-06-15 | — | — | EP | claimed |
| US-20220168240-A1 | CANCER THERAPY BY INTRATUMORAL INJECTION OF A CHEMOTHERAPEUTIC AGENT IN COMBINATION WITH A BIOACTIVE IMMUNOSTIMULATORY AGENT | SYBLEU INC. (US) | 2022-06-02 | — | — | US | claimed |
| EP-3982940-A1 | SONODYNAMIC THERAPY | Callan, John (GB) | 2022-04-20 | — | — | EP | claimed |
| CN-114344482-A | Multifunctional nanoparticle based on metal organic framework and preparation method and application thereof | 重庆医科大学附属第二医院 | 2022-04-15 | — | — | CN | claimed |
| CN-114206435-A | Treatment of central nervous system disorders | 诺欧生物有限责任公司 | 2022-03-18 | — | — | CN | claimed |
| US-20220062417-A1 | THERAPY | INNOVATION ULSTER LIMITED (GB) | 2022-03-03 | — | — | US | claimed |
| CN-114028565-A | 3D-COF drug-loading system for treating breast cancer and preparation method thereof | 江南大学 | 2022-02-11 | — | — | CN | claimed |
| EP-1951213-B1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | MORVUS TECHNOLOGY LTD (GB) | 2012-11-14 | — | — | EP | claimed |
| US-20100104515-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | GORDIAN PHARMA LIMITED (GB) | 2010-04-29 | — | — | US | claimed |
| EP-0450021-B1 | ANTI-CANCER COMPOUNDS | BRITISH TECH GROUP (GB) | 1994-02-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104515-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | DERA, HOGA1, ALDOA | NQO1 68/4885CYP19A1 1595/4885MEN1 4352/4885 |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CD47, TFRC, L1CAM | NQO1 4198/4885CYP19A1 4051/4885MEN1 3595/4885 |
| US-20220062417-A1 | THERAPY | CD274, PDCD1, PDCD1LG2 | NQO1 4151/4885CYP19A1 4789/4885MEN1 423/4885 |
| US-12564728-B2 | Treatment of central nervous system disorders | BDNF, NTRK2, CNTN1 | NQO1 537/4885CYP19A1 175/4885MEN1 2358/4885 |
| US-12584131-B2 | Methods of gene therapy | CYP7A1, POR, CYP4A22 | NQO1 498/4885CYP19A1 54/4885MEN1 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.